CO5150225A1 - Derivados del tetrahidropirano y su uso como agentes terapeuticos - Google Patents
Derivados del tetrahidropirano y su uso como agentes terapeuticosInfo
- Publication number
- CO5150225A1 CO5150225A1 CO00017612A CO00017612A CO5150225A1 CO 5150225 A1 CO5150225 A1 CO 5150225A1 CO 00017612 A CO00017612 A CO 00017612A CO 00017612 A CO00017612 A CO 00017612A CO 5150225 A1 CO5150225 A1 CO 5150225A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkoxy
- ring
- hydrogen
- substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- -1 C1- fluoroalkoxy 6 Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 2
- 241000036848 Porzana carolina Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto de la fórmula (I)<EMI FILE="00017612_1" ID="1" IMF=JPEG >en la queR1 es hidrógeno, halógeno, alquilo C1-6, alcoxi C1-6, fluoroalquilo C1-6, fluoroalcoxi C1-6, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, NO2, CN, SRa, SORa, SO2Ra, CO2Ra, CONRaRb, alquenilo C2-6, alquinilo C2-6 o alquilo C1-4 sustituido por alcoxi C1-4, en la que Ra y Rb representan cada uno independientemente hidrógeno o alquilo C1-4;R2 es hidrógeno, halógeno, alquilo C1-6 , fluoroalquilo C1-6 o alcoxi C1-6 sustituido por alcoxi C1-4;R3 es hidrógeno, halógeno o fluoroalquilo C1-6;R4 es hidrógeno, halógeno, alquilo C1-6, alcoxi C1-6, fluoroalquilo C1-6, fluoroalcoxi C1-6, hidroxi, NO2, CN, SRa, SORa, SO2Ra, CO2Ra, CONRaRb, alquenilo C2-6, alquinilo C2-6 o alquilo C1-4, sustituido por alcoxi C1-4, en el que Ra y Rb son tal como se han definido previamente;R5 es hidrógeno, halógeno, alquilo C1-6, fluoroalquilo C1-6 o alcoxi C1-6 sustituido por alcoxi C1-4;R6 representa hidrógeno o un grupo alquilo C1-4 opcionalmente sustituido por un grupo hidroxi;R7 representa halógeno, hidroxi, alquenilo C2-4, N3, -NR11R12, -NRaCORb, -OSO2Ra, -(CH2)pNRa(CH2)qCOORb, CORa, COORa, o un anillo heteroaromático de cinco miembros o de seis miembros que contiene nitrógeno que contiene opcionalmente 1, 2 ó 3 heteroátomos adicionales seleccionados entre N, O y S, anillo heteroaromático que está opcionalmente sustituido en cualquier posición sustituible por un sustituyente seleccionado entre =O, =S, halógeno, hidroxi, -SH, CORa, C02Ra, -ZNR11R12, alquilo C1-4, hidroxialquilo C1-4, fluoroalquilo C1-4, alcoxi C1-4, fluoroalcoxi C1-4 o alcoxi C1-4 sustituido por un grupo alcoxi C1-4 o hidroxi;R8 representa hidrógeno, alquilo C1-6, fluoroalquilo C1-6, hidroxi, alcoxi C1-6 o hidroxialquilo C1-6;R9 y R10 representan cada uno independientemente hidrógeno, halógeno, alquilo C1-6, CH20Rc, oxo, C02Rao CONRaRb donde Ra y Rb son tal como se han definido previamente y Rc representa hidrógeno, alquilo C1-6 o fenilo;R11 es hidrógeno, alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, alquilo C2-4 sustituido por un grupo alcoxi C1-4 o hidroxi, o R11 es un anillo heteroaromático de cinco miembros o de seis miembros que contiene nitrógeno, tal como se ha definido previamente;- 2 -R12 es hidrógeno o alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, o alquilo C2-4 sustituido por un grupo alcoxi C1-4 o hidroxi;o R11, R12 y el átomo de nitrógeno al que están unidos forman un anillo heteroalifático de 4 a 7 átomos en anillo, sustituidos opcionalmente por uno o dos grupos seleccionados entre hidroxi, CORe, C02Re, alquilo C1-4 opcionalmente sustituido por un grupo alcoxi C1-4 o hidroxilo, o alcoxi C1-4 opcionalmente sustituido por un grupo alcoxi C1-4 o hidroxilo, o un anillo heteroaromático de cinco miembros o de seis miembros que contiene nitrógeno tal como se ha definido previamente, o dicho anillo heteroalifático está sustituido por un anillo de lactona condensado en espiral, y dicho anillo heteroalifático contiene opcionalmente un doble enlace, anillo heteroalifático que puede contener opcionalmente un átomo de oxígeno o de azufre en el anillo, un grupo S(O) o S(O)2 o un segundo átomo de nitrógeno que formará parte de un radical NH o NRd, en el que Rd es alquilo C1-4 opcionalmente sustituido por hidroxi o alcoxi C1-4, y en el que Re es hidrógeno, alquilo C1-4 o bencilo;o R11, R12 y el átomo de nitrógeno al que están unidos forman un sistema de anillo azabicíclico no aromático de 6 a 12 átomos en anillo;o R11, R12 y el átomo de nitrógeno al que están unidos forman un anillo heteroalifático de 4 a 7 átomos en anillo, al cual está condensado un anillo de benceno o un anillo heteroaromático de cinco miembros o de seis miembros que contiene nitrógeno que contiene opcionalmente 1, 2 ó 3 heteroátomos adicionales seleccionados entre N, O y S;Z representa un enlace, alquileno C1-6 o cicloalquileno C3-6; n es cero, 1 ó 2;p es 1 ó 2; yq es 1 ó 2;y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9906480.0A GB9906480D0 (en) | 1999-03-19 | 1999-03-19 | Therapeutic agents |
GBGB9924616.7A GB9924616D0 (en) | 1999-10-18 | 1999-10-18 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5150225A1 true CO5150225A1 (es) | 2002-04-29 |
Family
ID=26315315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00017612A CO5150225A1 (es) | 1999-03-19 | 2000-03-10 | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
Country Status (23)
Country | Link |
---|---|
US (1) | US6458830B1 (es) |
EP (1) | EP1165540B1 (es) |
JP (1) | JP2002540107A (es) |
KR (1) | KR20010113773A (es) |
CN (1) | CN1344264A (es) |
AT (1) | ATE247096T1 (es) |
AU (2) | AU3304400A (es) |
BG (1) | BG105859A (es) |
BR (1) | BR0009127A (es) |
CA (1) | CA2367985A1 (es) |
CO (1) | CO5150225A1 (es) |
CZ (1) | CZ20013377A3 (es) |
DE (1) | DE60004504T2 (es) |
EA (1) | EA200100902A1 (es) |
EE (1) | EE200100491A (es) |
ES (1) | ES2203434T3 (es) |
HU (1) | HUP0200441A3 (es) |
IL (1) | IL144236A0 (es) |
NO (1) | NO20014529L (es) |
PE (1) | PE20001556A1 (es) |
PL (1) | PL350123A1 (es) |
SK (1) | SK13322001A3 (es) |
WO (2) | WO2000056728A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10001785A1 (de) * | 2000-01-18 | 2001-07-19 | Boehringer Ingelheim Pharma | NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms |
GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB0020721D0 (en) | 2000-08-22 | 2000-10-11 | Merck Sharp & Dohme | Therapeutic agents |
PE20020444A1 (es) | 2000-09-22 | 2002-06-14 | Merck & Co Inc | Antagonistas de receptores de taquiquinina zwitterionica |
EP1377565A1 (en) * | 2001-01-17 | 2004-01-07 | MERCK SHARP & DOHME LTD. | Tetrahydropyran derivatives as neurokinin receptor antagonists |
GB0121874D0 (en) * | 2001-09-10 | 2001-10-31 | Merck Sharp & Dohme | Therapeutic agents |
GB0217068D0 (en) * | 2002-07-23 | 2002-08-28 | Merck Sharp & Dohme | Therapeutic agents |
EP1562975A2 (en) * | 2002-10-25 | 2005-08-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
WO2004050084A2 (en) * | 2002-11-29 | 2004-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and nitricoxid-donor activity |
US7393858B2 (en) | 2003-03-07 | 2008-07-01 | Merck Sharp & Dohme Ltd. | Tetrahydropyran compounds as tachykinin antagonists |
US7589205B2 (en) | 2004-09-08 | 2009-09-15 | Nycomed Gmbh | 3-thia-10-aza-phenanthrene derivatives |
EP1819661B1 (en) * | 2004-11-30 | 2009-04-22 | Mallinckrodt, Inc. | Crystallization method for benzphetamine |
TW200642683A (en) * | 2005-04-22 | 2006-12-16 | Sankyo Co | Heterocyclic compound |
CN100395242C (zh) * | 2006-06-08 | 2008-06-18 | 华东理工大学 | 烷氧基萘和萘醌类吡喃碳糖苷化合物及其制备方法 |
DE102007010077B4 (de) * | 2007-02-28 | 2010-04-08 | RUHR-UNIVERSITäT BOCHUM | [1,3]-Dioxane zur Modulation von GABAa-Rezeptoren |
US9782397B2 (en) | 2011-07-04 | 2017-10-10 | Irbm Science Park S.P.A. | Treatment of corneal neovascularization |
AU2013312819A1 (en) * | 2012-09-04 | 2015-03-26 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
BR112016028255A2 (pt) | 2014-06-06 | 2017-08-22 | Flexus Biosciences Inc | agentes imunorreguladores |
AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
CN107205970A (zh) * | 2014-11-05 | 2017-09-26 | 弗莱塞斯生物科学公司 | 免疫调节剂 |
HU231150B1 (hu) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására |
JP7183196B2 (ja) * | 2018-02-06 | 2022-12-05 | 第一三共株式会社 | アミノアルキル化合物 |
CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9301920D0 (en) * | 1993-02-01 | 1993-03-17 | Foundation For Ethnobiology Th | Polycetylenes |
-
2000
- 2000-03-10 CO CO00017612A patent/CO5150225A1/es unknown
- 2000-03-13 PE PE2000000218A patent/PE20001556A1/es not_active Application Discontinuation
- 2000-03-16 US US09/936,343 patent/US6458830B1/en not_active Expired - Fee Related
- 2000-03-16 WO PCT/GB2000/000977 patent/WO2000056728A1/en not_active Application Discontinuation
- 2000-03-16 IL IL14423600A patent/IL144236A0/xx unknown
- 2000-03-16 EA EA200100902A patent/EA200100902A1/ru unknown
- 2000-03-16 JP JP2000606588A patent/JP2002540107A/ja not_active Withdrawn
- 2000-03-16 DE DE60004504T patent/DE60004504T2/de not_active Expired - Fee Related
- 2000-03-16 BR BR0009127-8A patent/BR0009127A/pt not_active Application Discontinuation
- 2000-03-16 PL PL00350123A patent/PL350123A1/xx not_active Application Discontinuation
- 2000-03-16 ES ES00911045T patent/ES2203434T3/es not_active Expired - Lifetime
- 2000-03-16 EP EP00911045A patent/EP1165540B1/en not_active Expired - Lifetime
- 2000-03-16 AT AT00911045T patent/ATE247096T1/de not_active IP Right Cessation
- 2000-03-16 CN CN00805114A patent/CN1344264A/zh active Pending
- 2000-03-16 AU AU33044/00A patent/AU3304400A/en not_active Abandoned
- 2000-03-16 SK SK1332-2001A patent/SK13322001A3/sk unknown
- 2000-03-16 HU HU0200441A patent/HUP0200441A3/hu unknown
- 2000-03-16 CA CA002367985A patent/CA2367985A1/en not_active Abandoned
- 2000-03-16 KR KR1020017011885A patent/KR20010113773A/ko not_active Application Discontinuation
- 2000-03-16 WO PCT/GB2000/000974 patent/WO2000056727A1/en active IP Right Grant
- 2000-03-16 AU AU33042/00A patent/AU746251B2/en not_active Ceased
- 2000-03-16 EE EEP200100491A patent/EE200100491A/xx unknown
- 2000-03-16 CZ CZ20013377A patent/CZ20013377A3/cs unknown
-
2001
- 2001-08-30 BG BG105859A patent/BG105859A/bg unknown
- 2001-09-18 NO NO20014529A patent/NO20014529L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2203434T3 (es) | 2004-04-16 |
EA200100902A1 (ru) | 2002-02-28 |
CN1344264A (zh) | 2002-04-10 |
AU746251B2 (en) | 2002-04-18 |
AU3304400A (en) | 2000-10-09 |
IL144236A0 (en) | 2002-05-23 |
BR0009127A (pt) | 2001-12-26 |
EE200100491A (et) | 2002-12-16 |
NO20014529L (no) | 2001-11-13 |
PL350123A1 (en) | 2002-11-04 |
NO20014529D0 (no) | 2001-09-18 |
ATE247096T1 (de) | 2003-08-15 |
AU3304200A (en) | 2000-10-09 |
BG105859A (bg) | 2002-04-30 |
HUP0200441A3 (en) | 2002-09-30 |
CZ20013377A3 (cs) | 2002-02-13 |
DE60004504D1 (de) | 2003-09-18 |
PE20001556A1 (es) | 2001-01-13 |
EP1165540A1 (en) | 2002-01-02 |
DE60004504T2 (de) | 2004-06-24 |
JP2002540107A (ja) | 2002-11-26 |
US6458830B1 (en) | 2002-10-01 |
SK13322001A3 (sk) | 2002-02-05 |
KR20010113773A (ko) | 2001-12-28 |
CA2367985A1 (en) | 2000-09-28 |
WO2000056728A1 (en) | 2000-09-28 |
WO2000056727A1 (en) | 2000-09-28 |
HUP0200441A2 (hu) | 2002-07-29 |
EP1165540B1 (en) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5150225A1 (es) | Derivados del tetrahidropirano y su uso como agentes terapeuticos | |
AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
AR049551A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR033344A1 (es) | Compuestos derivados de benzofenonas como inhibidores de la transcriptasa inversa, su uso en la fabricacion de medicamentos, intermediarios y composiciones farmaceuticas | |
AR054799A1 (es) | Derivados de oxindol | |
AR049664A1 (es) | Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits. | |
CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR057107A2 (es) | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos | |
AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
AR047706A1 (es) | Inhibidores de polimerasa viral | |
CO5261551A1 (es) | Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas | |
AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
AR039661A1 (es) | Inhibidores de la triaril-oxi-aril-espiro-pirimidin-2,4,6-triona metaloproteinasa | |
CO5261601A1 (es) | Indolilquinolinonas utiles como inhibidores de la tirosinoquinasa | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
AR013815A1 (es) | NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. | |
UY25857A1 (es) | 4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks) | |
RU2009143753A (ru) | Производные n'-(фенил)-n-(морфолин-4-ил-пиридин-2-ил)-пиримидин-2, 4-идиамина в качестве ингибиторов ернв4 киназы для лечения пролиферативных состояний | |
CO5080791A1 (es) | Derivados de la piperidina que tienen efectos sobre sistemas con serotonina |